Published in Cancer on September 01, 2008
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) (2010) 1.30
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J (2009) 1.20
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One (2013) 1.10
Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol (2011) 1.00
Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Radiat Oncol (2013) 0.96
Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. Liver Cancer (2014) 0.95
Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol (2013) 0.95
Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol (2014) 0.94
Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One (2013) 0.93
Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol (2009) 0.92
The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver (2012) 0.90
Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer (2013) 0.90
Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer (2016) 0.87
Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. Liver Cancer (2012) 0.87
Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J (2013) 0.87
Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. J Radiat Res (2013) 0.83
Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. J Radiat Res (2013) 0.82
Current management of hepatocellular carcinoma: an Eastern perspective. World J Gastroenterol (2015) 0.82
Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Cancer Res Treat (2015) 0.81
Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma. Yonsei Med J (2014) 0.81
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World J Gastroenterol (2016) 0.81
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer (2014) 0.79
Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther (2013) 0.78
Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. Yonsei Med J (2016) 0.77
Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med (2012) 0.76
Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J (2016) 0.75
Early experience of helical tomotherapy for hepatobiliary radiotherapy. Case Reports Hepatol (2011) 0.75
Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy. Curr Oncol (2014) 0.75
Which treatment modality should we choose for advanced hepatocellular carcinoma? Korean J Hepatol (2010) 0.75
Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma. Liver Cancer (2016) 0.75
Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis. Clin Proteomics (2017) 0.75
Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study. Radiat Oncol (2017) 0.75
Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2002) 2.18
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology (2011) 1.87
Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int (2007) 1.80
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol (2003) 1.79
Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol (2004) 1.77
Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res (2012) 1.67
Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol (2009) 1.66
The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol (2012) 1.63
Clarification required for the definition of hepatitis B virus subgenotypes C1 and C2. Intervirology (2009) 1.60
Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys (2003) 1.56
Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol (2008) 1.55
Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys (2007) 1.54
Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology (2011) 1.48
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Outcomes of endovascular management for complicated chronic type B aortic dissection: effect of the extent of stent graft coverage and anatomic properties of aortic dissection. J Vasc Interv Radiol (2013) 1.47
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. Liver Int (2010) 1.46
Variability in liver stiffness values from different intercostal spaces. Liver Int (2009) 1.45
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One (2012) 1.43
Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol (2004) 1.39
Coupling bifurcated stent-grafts to overcome anatomic limitations of endovascular repair of abdominal aortic aneurysms. J Vasc Interv Radiol (2012) 1.39
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol (2012) 1.37
Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int (2005) 1.37
Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci (2008) 1.35
Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology (2008) 1.35
Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol (2008) 1.34
Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology (2007) 1.33
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology (2011) 1.29
Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int (2013) 1.27
Outcome after curative resection for a huge (>or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg (2009) 1.26
HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther (2011) 1.26
Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int (2010) 1.25
MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis (2008) 1.25
Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One (2012) 1.24
MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics (2007) 1.23
Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology (2007) 1.21
Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int (2007) 1.21
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther (2010) 1.18
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol (2010) 1.18
Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol (2009) 1.17
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J (2005) 1.17
Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol (2006) 1.17
Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci (2014) 1.16
Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys (2003) 1.15
A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. Am J Gastroenterol (2010) 1.15
Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol (2007) 1.15
Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int (2010) 1.15
Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol (2011) 1.14
Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci (2012) 1.14
Discordance between liver biopsy and Fibroscan® in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation. PLoS One (2012) 1.13
Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol (2004) 1.13
Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One (2012) 1.12
How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol (2010) 1.12
Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology (2010) 1.11
Percutaneous treatment of deep vein thrombosis in May-Thurner syndrome. Cardiovasc Intervent Radiol (2006) 1.11
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer (2007) 1.11